Technical Analysis for SLRN - Acelyrin Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Buy Signal | Bullish | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Bullish Engulfing | Bullish | -6.14% | |
| Lower Bollinger Band Walk | Weakness | -6.14% | |
| Wide Bands | Range Expansion | -6.14% |
| Alert | Time |
|---|---|
| Outside Day | about 18 hours ago |
| Fell Below Previous Day's Low | about 18 hours ago |
| Down 5% | about 18 hours ago |
| 60 Minute Opening Range Breakdown | about 19 hours ago |
| Rose Above Previous Day's High | about 22 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/13/2024
Acelyrin Inc. Description
ACELYRIN, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Drugs Monoclonal Antibodies Uveitis Psoriatic Arthritis Hidradenitis Suppurativa Thyroid Eye Disease Chronic Urticaria Duligotuzumab
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.885 |
| 52 Week Low | 3.36 |
| Average Volume | 716,381 |
| 200-Day Moving Average | 5.57 |
| 50-Day Moving Average | 5.39 |
| 20-Day Moving Average | 5.65 |
| 10-Day Moving Average | 5.34 |
| Average True Range | 0.44 |
| RSI (14) | 31.03 |
| ADX | 22.5 |
| +DI | 14.49 |
| -DI | 30.56 |
| Chandelier Exit (Long, 3 ATRs) | 5.17 |
| Chandelier Exit (Short, 3 ATRs) | 5.60 |
| Upper Bollinger Bands | 6.79 |
| Lower Bollinger Band | 4.51 |
| Percent B (%b) | -0.04 |
| BandWidth | 40.34 |
| MACD Line | -0.22 |
| MACD Signal Line | -0.02 |
| MACD Histogram | -0.2014 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.06 | ||||
| Resistance 3 (R3) | 5.13 | 4.98 | 4.96 | ||
| Resistance 2 (R2) | 4.98 | 4.82 | 4.95 | 4.92 | |
| Resistance 1 (R1) | 4.71 | 4.72 | 4.64 | 4.64 | 4.88 |
| Pivot Point | 4.56 | 4.56 | 4.53 | 4.53 | 4.56 |
| Support 1 (S1) | 4.29 | 4.40 | 4.22 | 4.22 | 3.98 |
| Support 2 (S2) | 4.14 | 4.30 | 4.11 | 3.94 | |
| Support 3 (S3) | 3.87 | 4.14 | 3.91 | ||
| Support 4 (S4) | 3.80 |
